Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
- Opdivo Price Cut Won’t Have Much Impact on Financial Results: Ono
August 27, 2018
- Pfizer, Astellas Move UP Completion Dates for 2 Xtandi Studies
August 24, 2018
- Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
August 24, 2018
- Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
August 24, 2018
- Lenvima Approved for 1st Line HCC Use in Europe: Eisai/Merck
August 24, 2018
- Shire Japan, Medipal Introduce Emergency Delivery System for Hemophilia Treatment
August 23, 2018
- MSD Launches Antibacterial Agent Sivextro
August 23, 2018
- Takeda, Ono Join Hands in Japan PIII for Opdivo-Cabozantinib Combo
August 23, 2018
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- Otsuka Grabs Rights to Osaka Univ. CAR-T Therapy
August 22, 2018
- Daiichi Sankyo Espha Unveils Authorized Generic Pact with AstraZeneca, 3 More Oncology AGs Pending Approval
August 21, 2018
- New Anti-Parkinson’s Drug Obtains POC in PIIa Study: Kyowa Kirin
August 21, 2018
- Japanese OTC Drug Market Grew 1.0% to 828 Billion Yen in 2017: Yano Research
August 21, 2018
- Japan’s 1st Herceptin Biosimilar Now Available, but Use Limited to Gastric Cancer
August 21, 2018
- Mitsubishi Tanabe Going Digital to Shed Drug Discovery and Sales Outlays: President
August 21, 2018
- I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
August 20, 2018
- Roche Diagnostics’ EGFR Mutations Test Kit Approved for Determining 1st Line Treatment of Tagrisso
August 20, 2018
- Solasia Licenses PTCL Treatment to Columbia Firm in Latin America
August 20, 2018
- Taiho Files Lonsurf for Gastric Cancer in Japan
August 20, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…